July 29, 2021 07:23 AM EDTUpdated July 30, 03:35 PM

AstraZeneca and Amgen quietly admit tezepelumab setback as the Dupixent challenger heads to FDA

Max Gelman

Senior Editor

AstraZeneca and Amgen have blockbuster ambitions for their tezepelumab antibody, aiming to challenge the Regeneron and Sanofi giant Dupixent in asthma and related respiratory maladies …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca and Amgen quietly admit tezepelumab setback as the Dupixent challenger heads to FDA

Max Gelman

Senior Editor

Sign up to read this article for free.

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Bristol Myers reveals more job cuts in New Jersey

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Minnesota 340B revenue driven by hospitals and high-priced drugs, first state report says

As­traZeneca and Am­gen qui­et­ly ad­mit teze­pelum­ab set­back as the Dupix­ent chal­lenger heads to FDA

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Bris­tol My­ers re­veals more job cuts in New Jer­sey

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Min­neso­ta 340B rev­enue dri­ven by hos­pi­tals and high-priced drugs, first state re­port says

AstraZeneca and Amgen quietly admit tezepelumab setback as the Dupixent challenger heads to FDA

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Bristol Myers reveals more job cuts in New Jersey

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Minnesota 340B revenue driven by hospitals and high-priced drugs, first state report says